Scilex Holding (SCLX) EBITDA Margin Growth (1y) (2023 - 2026)
Scilex Holding (SCLX) EBITDA Margin Growth (1y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.84 Bn | 633.08 Bn | 17.26 Bn | 22.00 |
| 2 | AbbVie | 470.10 Bn | 463.53 Bn | 12.70 Bn | 613.00 |
| 3 | Merck | 376.16 Bn | 369.02 Bn | 12.21 Bn | -3,510.00 |
| 4 | Novartis Ag | 303.94 Bn | 296.25 Bn | 11.24 Bn | -164.00 |
| 5 | Astrazeneca | 257.99 Bn | 253.09 Bn | 12.86 Bn | -370.00 |
| 6 | Amgen | 236.45 Bn | 222.46 Bn | 7.24 Bn | 602.00 |
| 7 | Gilead Sciences | 182.10 Bn | 178.92 Bn | 6.22 Bn | -16,814.00 |
| 8 | Pfizer | 159.60 Bn | 147.90 Bn | 10.94 Bn | -611.00 |
| 9 | Gsk | 106.32 Bn | 102.15 Bn | 8.24 Bn | -1,961.00 |
| 10 | Scilex Holding | 40.37 Mn | -72.42 Mn | 3.97 Mn | -17,788.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18,390.00 |
| Dec 31, 2025 | -210,492.00 |
| Sep 30, 2025 | -162,824.00 |
| Jun 30, 2025 | -11,179.00 |
| Mar 31, 2025 | -37,900.00 |
| Dec 31, 2024 | -5,410.00 |
| Sep 30, 2024 | 24,559.00 |
| Jun 30, 2024 | 8,589.00 |
| Mar 31, 2024 | 6,176.00 |
| Dec 31, 2023 | 2,940.00 |
| Sep 30, 2023 | -29,025.00 |
| Jun 30, 2023 | -3,660.00 |
| Mar 31, 2023 | -11,145.00 |